JDRF T1D Fund

Zucara Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics to prevent hypoglycemia, or low blood sugar, in patients with diabetes. Established in 2014 and headquartered in Toronto, Canada, with an additional office in Vancouver, Zucara is pioneering a once-daily treatment that aims to regulate the hormone somatostatin in the pancreas. This treatment specifically targets somatostatin type 2 receptors, which are not effectively controlled in patients with Type 1 diabetes. Zucara's approach presents a significant advancement in diabetes care by functioning as a preventative measure against hypoglycemia, contrasting with existing therapies that only provide rescue during acute episodes. Through its pre-clinical technology, Zucara Therapeutics aims to restore natural glucose levels in the blood, ultimately enhancing the quality of life for individuals living with diabetes.

Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, specializing in 3D bioprinting and tissue engineering. Founded in 2013, the company leverages proprietary microfluidic 3D bioprinting technology to develop bioprinted tissue therapeutics aimed at transforming disease treatment. By integrating therapeutic cells and materials science, Aspect Biosystems creates allogeneic cell-based tissue therapeutics that can replace or repair damaged organ functions. The company also provides a Lab-on-a-printer technology that allows precise control over biomaterial composition and structure during tissue fabrication. Its innovative platform supports the development of novel therapeutics and enhances understanding in fundamental biology and disease research, catering to pharmaceutical firms and academic institutions focused on respiratory diseases and regenerative medicine. Aspect Biosystems is actively collaborating with researchers and industry leaders to address significant challenges in the field of regenerative medicine.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

vTv Therapeutics LLC is a clinical-stage biopharmaceutical company dedicated to the discovery and development of orally administered small molecule therapeutics aimed at addressing unmet medical needs across a variety of human diseases. The company has a diverse pipeline that includes drug candidates targeting central nervous system disorders, diabetes, inflammation, and cancer, with a primary focus on Alzheimer's disease and Type 2 diabetes. Notable candidates in development include Azeliragon, which is in Phase II clinical trials for mild Alzheimer's disease, and TTP399, a liver-selective glucokinase activator that has completed Phase II trials for Type 2 diabetes. vTv Therapeutics is also advancing additional compounds such as TTP273 and HPP737, among others, to tackle chronic diseases. Founded in 1998 and based in High Point, North Carolina, vTv Therapeutics operates as a subsidiary of vTv Therapeutics Inc. and emphasizes a commitment to innovative drug discovery through its in-house research and strategic collaborations.

Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

DiogenX is a preclinical stage biotechnology company based in Marseille, France, with research facilities in Nice. Founded in 2019, it specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of both Type 1 and Type 2 diabetes. The company aims to create a candidate molecule that regenerates pancreatic insulin-producing cells, which could significantly improve the quality of life and survival rates for individuals with diabetes. This innovative approach has the potential to become a groundbreaking therapy for beta-cell regeneration in diabetes management, stemming from research conducted in the laboratory of Dr. Patrick Collombat.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company specializes in developing treatments that target nonworking or missing genes by introducing healthy copies back into the body to restore function. This approach aims to address significant unmet needs in healthcare by expediting the development of gene therapies from research to clinical application as safely and quickly as possible.

Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

Egle Therapeutics SAS is a biotechnology company founded in 2020 and based in Paris, France. The company specializes in developing immunotherapies aimed at targeting immune suppressor regulatory T-cells (Tregs) to address oncology and autoimmune diseases. Egle Therapeutics is focused on its proprietary pipeline, which includes a series of computationally designed IL-2 variants designed to modulate Tregs by either engaging or disengaging them from tumor environments. Through its innovative approach to Treg modulation, the company aims to enable healthcare professionals to develop new therapies that effectively target these immune suppressor cells, potentially transforming treatment options for cancer and other diseases.

GentiBio, Inc. is a biotherapeutics company that specializes in developing engineered regulatory T cells, known as EngTregs, aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, Washington, GentiBio employs a proprietary platform that combines autologous and allogeneic technologies. This platform enhances the ability to restore immune tolerance and addresses significant limitations found in existing regulatory T-cell therapeutics. By focusing on the underlying mechanisms of immune system disorders, GentiBio aims to provide innovative therapeutic solutions that tackle the root causes of diseases caused by dysregulated immune responses. The company is co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of advanced immunotherapy development.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

Abata Therapeutics is a biotechnology company dedicated to developing innovative cell therapies for patients suffering from progressive multiple sclerosis and other severe autoimmune and inflammatory diseases. The company specializes in the manipulation of regulatory T cells (Tregs) to address these conditions, aiming to restore balance within the immune system. By engineering Tregs to precisely target disease-related antigens, Abata Therapeutics creates therapies that can effectively treat diseases such as multiple sclerosis and type 1 diabetes without imposing systemic immune suppression. Founded by experts in immunology and cell therapy, Abata is committed to translating advanced scientific research into meaningful therapies that improve the lives of individuals facing chronic autoimmune challenges.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Seraxis is a private biotechnology company established in March 2013, with operations in both Singapore and the United States. The company has a GMP lab located in Germantown, Maryland, where a team of scientists has developed innovative cell and encapsulation technologies. Seraxis is dedicated to creating a practical cell therapy aimed at treating insulin-dependent diabetes. Their primary objective is to provide a long-term cure for patients that does not necessitate the use of immunosuppression, thereby addressing a critical need in diabetes care. By focusing on the production of insulin to regulate glucose levels, Seraxis aims to enhance the quality of life for diabetic patients through its advanced therapeutic solutions.

Protomer Technologies Inc. is a pre-clinical stage biotechnology company based in Pasadena, California, founded in 2014. The company specializes in the development of therapeutic proteins and peptides through its proprietary platform known as Molecular Engineering of Protein Sensors (MEPS). This innovative platform allows for the creation of proteins that can sense molecular activators in the body and be activated as needed, facilitating variable dosing and targeted delivery. Protomer's research primarily focuses on metabolic diseases, with a notable product being a glucose-responsive insulin designed to help manage rising sugar levels in individuals with diabetes. Through its advanced protein-engineering capabilities, Protomer Technologies aims to enhance treatment options for patients suffering from metabolic conditions.

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Woodstock, Georgia, focused on developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, dermatology, animal health, eye care, and oral care. With over 100 products commercialized in 33 countries, Sonoma addresses unmet medical needs through its innovative therapies aimed at chronic skin conditions. Key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for dermatoses; Celacyn gel for scar management; and SebuDerm for seborrheic dermatitis. Additionally, the company provides Microcyn, which targets various pathogens to promote wound healing, and Acuicyn, designed for eye care. Sonoma Pharmaceuticals was formerly known as Oculus Innovative Sciences, Inc. and has been incorporated since 1999. Its commitment to improving patient care and reducing healthcare costs is reflected in its diverse product portfolio that caters to both prescription and non-prescription needs.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

DiogenX is a preclinical stage biotechnology company based in Marseille, France, with research facilities in Nice. Founded in 2019, it specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of both Type 1 and Type 2 diabetes. The company aims to create a candidate molecule that regenerates pancreatic insulin-producing cells, which could significantly improve the quality of life and survival rates for individuals with diabetes. This innovative approach has the potential to become a groundbreaking therapy for beta-cell regeneration in diabetes management, stemming from research conducted in the laboratory of Dr. Patrick Collombat.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

i2O Therapeutics, established in 2019 and headquartered in Saratoga, California, specializes in converting injectable biologic therapies into orally administrable pills using its proprietary ionic liquid technology. This innovative approach aims to enhance the permeability of epithelial barriers, enabling safe and effective oral delivery of peptides, proteins, and other traditionally injected drugs. The company focuses on developing next-generation oral therapies for metabolic and inflammatory diseases.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Repertoire Immune Medicines, Inc. is a clinical stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company focuses on harnessing the power of T cells to develop innovative treatments for cancer, autoimmune diseases, and infectious diseases. By utilizing autologous T cells that are primed against specific cancer antigens and tethered to IL-15, Repertoire Immune Medicines aims to unlock and direct the human immune system to effectively prevent and treat various conditions. The company also specializes in characterizing T cell receptor (TCR)-antigen pairs and rationally designing targeted immune medicines, thereby enhancing the potential for effective therapies in serious health challenges.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.

IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore immune tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT is working on a functional T-cell test to facilitate the diagnosis and monitoring of immune tolerance in patients undergoing peptide-based therapy. Through its innovative approach, the company seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Capillary Biomedical, Inc. is a medical device company based in Irvine, California, established in 2014 as a spin-out from the Artificial Pancreas Center at the Sidney Kimmel Medical College. The company focuses on developing innovative technologies for diabetes management, aiming to simplify the processes of glucose monitoring and insulin delivery. Their signature product features a kink-proof, flexible, multiport cannula designed to enhance the reliability and comfort of insulin delivery. This user-friendly device allows for simple one-handed insertion, enabling diabetes patients to better manage their blood glucose levels and alleviating some of the burdens associated with diabetes on both individuals and the healthcare system.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Diasome Pharmaceuticals, Inc. is a clinical stage diabetes therapeutics company focused on designing and developing innovative insulin-based therapies for the treatment of Type 1 and Type 2 diabetes. Founded in 2004, the company is headquartered in Cleveland, Ohio. Diasome's flagship product, the hepatocyte directed vesicle (HDV), is a nanoscale carrier that delivers multiple insulin molecules directly to the liver and is compatible with all commercially available insulin delivery methods, including insulin pumps. The company also offers Oral HVD-I, a targeted oral insulin in pill or gel cap form, and injectable insulin options such as HDV-I, a short-acting formulation, and HDV-B, a long-acting formulation. Through its proprietary technology, Diasome aims to improve glycemic control and optimize insulin delivery systems for diabetes patients.

TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company employs its proprietary TetraExpress system to produce recombinant human ion channel proteins, which are essential for creating complex therapeutic agents. Among its offerings is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. TetraGenetics specializes in producing difficult-to-express eukaryotic membrane and secretory proteins, including vaccine antigens and monoclonal antibodies, which are crucial for treating various human and animal diseases. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., further enhancing its capabilities in therapeutic innovation.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

GluSense Ltd. is a healthcare technology company based in Lod, Israel, specializing in the development of a miniature implantable continuous glucose monitoring sensor. Founded in 2007, GluSense focuses on creating a minimally invasive device that can be implanted under the skin and provides accurate glucose measurements for over a year. This innovative sensor transmits real-time glucose values wirelessly to external devices, such as smartphones or wearables, significantly reducing the need for frequent blood glucose calibrations. By enabling individuals with diabetes to maintain their blood glucose levels within a safe range, GluSense aims to enhance the quality of life for patients managing this chronic condition.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company based in Oldwick, New Jersey, focused on developing and commercializing innovative therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's pipeline includes several product candidates, such as PRV-031 teplizumab, which is in Phase III trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor currently in Phase IIa trials for Crohn's disease. Additional candidates include PRV-3279 for lupus, PRV-101, a vaccine for coxsackie virus B infections, and PRV-015, an anti-IL-15 monoclonal antibody in Phase IIb trials for non-responsive celiac disease. Provention Bio's approach aims to reduce the burden of chronic autoimmune and inflammatory diseases through early intervention. The company was incorporated in 2016 and is committed to leveraging its expertise in translational medicine and immunology to efficiently develop and partner with clinical-stage assets.